**Appendix 3- Table A3. Three-year costs, medical outcomes, effectiveness and cost-effectiveness (N=1,525)**

|  |  |  |  |  |  |  |  |
| --- | --- | --- | --- | --- | --- | --- | --- |
| **N=****1,525** | **Costs (€2018)\*** | **Z Score at 3 years\*** | **Z Score Δ between 3 years and baseline** | **Frequency of aggravations** | **Percent of aggravations** | **Δ between intervention placebo groups** | **ICER||** |
|  | Mean[95% CI†] | Mean[95% CI†] | Mean[95% CI†] | N[95% CI†] | %[95% CI†] | Cost Δ | Z Score Δ | Δ N of no aggravation | Δ % of no aggravation | Z Score Δ | Δ N of no aggravation | Δ % of no aggravation |
| Placebo | 7,084[6,848; 7,331] | -0.051[-0.138; 0.036] | -0.069[-0.104; -0.041] | 323[309; 336] | 85[81.3; 88.4] | - | - | - | - | - | - | - |
| PFA§ | 8,321[8,045; 8,592] | -0.029[-0.112; 0.059] | -0.057[-0.094; -0.035] | 325[312; 339] | 85.3[81.2; 88.5] | 1,237 | 0.011 | 2 | 0.30 | 11,1720 | 618 | 4,098 |
| MI‡ | 8,789[8,496; 9,091] | 0.008[-0.088; 0.092] | 0.011[-0.023; 0.041] | 339[326; 352] | 86.9[83.6; 90.3] | 1,705 | 0.079 | 13 | 1.92 | 21,543 | 107 | 887 |
| PFA§ + MI‡ | 9,070[8,761; 9,369] | -0.019[-0.107; 0.064] | 0.024[-0.005; 0.049] | 335[323; 347] | 89.6[86.4; 92.8] | 1,986 | 0.093 | 12 | 4.57 | 21,443 | 166 | 434 |

\*Using fitted value from the multivariate analysis; †Confidence Interval; ‡Multidomain Intervention; §Polyunsaturated Fatty Acids; ||Incremental Cost-Effectiveness Ratio